Posts Tagged: PhRMA
Bipartisan Agreement That Drug Prices Are a Problem (and Patents are Complicated) Could Mean Changes for Pharma
During a hearing of the Senate Committee on the Judiciary on Tuesday titled, “Intellectual Property and the Price of Prescription Drugs: Balancing Innovation and Competition,” senators heard …
Athena Diagnostics Amici Warn of Harms to Biotech Revolution Under Current Alice/Mayo Framework
April 22 was the deadline for filing amicus briefs with the Court of Appeals for the Federal Circuit in Athena Diagnostics’ petition for an en banc rehearing by …
Other Barks & Bites for Friday, March 8
This week in Other Barks & Bites: The United Nations highlights the importance of women in innovation on International Women's Day; Comments due today on USPTO Section 101 Guidance; …
Examining the Truvada #BreakThePatent Debate: Gilead Responds
In July 2012, the U.S. Food and Drug Administration (FDA) first approved Truvada, an acquired immunodeficiency syndrome (AIDS) treatment manufactured by Gilead Sciences as a daily pre-exposure …
Analyzing Amicus Briefs Filed in Support of Granting Cert. in Helsinn
On June 25th, the the U.S. Supreme Court agreed to hear Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA Inc., on appeal from the Federal Circuit. …
China extends drug patent exclusivity to 25 years
Among members of the news media, patents have been a popular whipping boy when contemplating why Americans pay higher drug prices relative to the rest of the …
Manufacturing Firms and Organizations File Briefs in Oil States
Doubtless there are some manufacturing firms, such as Telebrands, who are great endorsers of inter partes review (IPR) proceedings at the Patent Trial and Appeal Board (PTAB) …
What are Legitimate Patent Rights and Who are Legitimate Patent Owners?
Use of this phrase strikes me as indefensible because by its very nature it implies picking winners and losers after the Patent Office has already issued a …
BIO, PhRMA lobby for IPR fix to insulate their patents from challenge
Greenwood and Castellani will have two major problems as they seek relief. First, the IPR provisions do not include a standing requirement, which means that anyone can …
Genetic and Stem Cell Therapies to Treat Cancers
There are certainly some signs for hope. One of them came recently from Princeton University, where graduate students worked on a project which identified a treatment for …
Pharma Law and Business: A Month Roundup for February 2013
The FDA decided not to pursue a re-hearing before a federal appeals court that recently ruled the federal government could not prosecute a sales rep who promoted …
